Inimmune https://validator.w3.org/feed/docs/rss2.html About Cancer Immunotherapy Allergy Immunotherapy Team Popup New Leadership Vaccination with ancestral SARS-CoV-2 spike adjuvanted with TLR agonists provides cross-protection against XBB.1 Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization Intranasal administration of a novel synthetic TLR4 agonist suppresses allergen-specific Th2 responses in mice A novel immunostimulatory TLR7/8 agonist is curative as a monotherapy in Lewis Lung Carcinoma and synergizes with anti-PD-1 in B16F10 and MC38 tumor models Careers Pipeline Investors Promotion of Th17 polarized immunity via co-delivery of Mincle agonist and Tuberculosis antigen using silica nanoparticles Co-delivery of a novel lipidated TLR7/8 agonist and hemagglutinin-based influenza antigen using silica nanoparticles promotes enhanced immune responses Terms of Service Co-delivery of novel synthetic TLR4 and TLR7/8 ligands adsorbed to aluminum salts promotes Th1-mediated immunity against poorly immunogenic SARS-CoV-2 RBD Diamino allose phosphates: Novel, potent, and highly stable Toll-like receptor 4 agonists Self-adjuvanting TLR7/8 agonist and fentanyl hapten co-conjugate achieves enhanced protection against fentanyl challenge Using Dual Toll-like Receptor Agonism to Drive Th1-BiasedResponse in a Squalene- andα-Tocopherol-ContainingEmulsion for a More Effective SARS-CoV-2 Vaccine TRAC478 Vaccine Adjuvant Opioid Vaccine News SAS Vaccine Adjuvant test Intranasal administration of a synthetic TLR4 agonist INI-2004 significantly reduces allergy symptoms following therapeutic administration in a murine model of allergic sensitization Inimmune announces collaboration with UChicago’s Pritzker School of Molecular Engineering (PME) professor Aaron Esser-Kahn to develop novel vaccine adjuvants Privacy Policy Inimmune Announces Successful Phase 1 Clinical Results For Disease Modifying Allergy Treatment, INI-2004 Inimmune Announces First Cancer Patient Dosed in Phase 1 Clinical Study Using the Immunotherapeutic INI-4001, a Novel TLR7/8 Agonist SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems Contact David Burkhart, Ph.D. Home Inimmune Co-Founder and Chief Scientific and Strategy Officer, Dr. Jay Evans, to be a featured panelist at the 2023 MT Economic Outlook Seminar Inimmune to Participate at World Vaccine Congress 2023 Inimmune to Present an Update on Clinical Stage Programs Inimmune to Participate and Update on Clinical Programs Inimmune to Provide an Update on Our Vaccine and Adjuvant Programs Inimmune to Present on Our Novel Cancer Immunotherapy INI-4001 Inimmune to present an Update on Clinical Stage Vaccine Adjuvant and Immunotherapy Programs at the World Vaccine Congress in Washington DC on April 1st Inimmune to Present at the Medinvest Oncology Conference on INI-4001 Science Behind the Silent Killer UM Receives Largest Single Research Award in its History For Missoula’s Inimmune, a $22 M Series A Round with Two Bear Capital is the latest record set Biotech Company Announces $22 Million Investment Led by Mike Goguen’s Firm Inimmune Welcomes New Chief Medical Officer Inimmune raises $22 Million in Series A Funding Led by Two Bear Capital Inimmune to Play a Key Role at the World Vaccine Congress Montana Biotech Company Receives $2 M Small Business Innovation Research Grant to Advance Vaccine Technologies